A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

Compared with placebo, pramipexole added to antidepressants reduces symptoms significantly at 12 weeks in treatment-resistant depression, a trial finds.

A drug used for Parkinson's disease has been shown to be effective in reducing the symptoms of difficult to treat depression, ...

An experimental psychedelic therapy from the U.K. company Beckley Psytech significantly reduced symptoms of ...

A single dose of a synthetic psilocybin was found to improve symptoms in patients with treatment-resistant depression.

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Despite a significant improvement in symptoms, around 20% of patients discontinued treatment due to adverse events.

In the largest clinical trial to date, pramipexole was found to be substantially more effective than a placebo at reducing the symptoms of treatment-resistant depression (TRD) over the course of ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the therapy.

Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of a planned merger with mental health-focused company Atai Life ...